

January 8, 2018



## **ZIVO Bioscience Subsidiary Wellmetris Selected to Present at Biotech Showcase During JPMorgan Healthcare Conference Jan 7-10 in San Francisco, CA**

KEEGO HARBOR, Mich., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO), a biotech/agtech R&D company, announced today that its WellMetris subsidiary will be presenting at the Biotech Showcase at the Hilton San Francisco Union Square hotel on Wednesday, January 10 during the JPMorgan Healthcare Conference held annually in the city of San Francisco. The juried selection process added WellMetris to the list of presenting companies several weeks ago and company principals have been preparing for the event.

WellMetris will be presenting its unique personal health tracking technology to an audience of analysts, investors and industry executives attending the many events that occur concurrently throughout the week. All-new WellMetris device designs, prototypes and user interface will be displayed and demonstrated. Company principals hope to engage strategic partners to assist in bringing the novel testing platform to market.

ZIVO Bioscience, Inc. president & CEO Andrew Dahl also participated in the China Showcase, which took place Sunday, January 7 at the same venue, to advance discussions on outsourcing algae production in mainland China on behalf of ZIVO.

### ***About ZIVO Bioscience, Inc.***

ZIVO Bioscience, Inc. (OTCQB:ZIVO) is a Michigan-based biotech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

ZIVO subsidiary WellMetris, LLC is a Delaware limited liability company wholly-owned by ZIVO Bioscience, Inc., which holds IP in the form of proprietary metabolic testing and analytics for humans and animals, to include assays, analyzers, collection devices and applications.

### ***Safe Harbor Statement***

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

**Contact:**

**Investor Relations**

**(248) 452 9866 ext 150**

**ZIVO Bioscience, Inc.**

[Investor@zivobioscience.com](mailto:Investor@zivobioscience.com)



Source: Zivo Bioscience, Inc.